CD274 and neoplasm: This has been particularly challenging in efforts of developing predictive biomarkers for cancer immunotherapy, where the only biomarker of outcomes for anti-PD1 therapy (tumor associated PDL1 expression) continues to be highly debated and remains of notable but limited clinical value.